The US Food and Drug Administration recently announced it is set to expand the Total Product Lifecycle Advisory Program (TAP) by enrolling devices from the Office of Neurological and Physical Medicine Devices (OHT5) beginning 1 October.
Currently, there are no neurological devices
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?